文献速递甲状腺疾病

仑伐替尼18mg与24mg起始剂量治疗放射性碘难治性分化型甲状腺癌的随机研究

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究为双盲随机研究,比较仑伐替尼24mg/日与18mg/日起始剂量治疗放射性碘难治性分化型甲状腺癌(RR-DTC)。主要疗效终点第24周客观缓解率(ORRwk24)在24mg组为57.3%(95%CI 46.1,68.5),18mg组为40.3%(95%CI 29.3,51.2),优势比(18/24mg)为0.50(95%CI 0.26,0.96)。18mg/日未达到相对于24mg/日的非劣效性,安全性特征相当。

要点

  • 仑伐替尼18mg/日起始剂量未达到24mg/日的非劣效性(ORRwk24优势比0.50,95%CI 0.26,0.96)。
  • 第24周ORR在24mg组为57.3%,18mg组为40.3%,差异具有临床意义。
  • 两组≥3级治疗中出现的不良事件(TEAE)发生率差异无临床相关性。

核心结论

  • 在RR-DTC患者中,仑伐替尼18mg/日起始剂量未达到相对于24mg/日的非劣效性(基于ORRwk24)。
  • ORRwk24的差异具有临床意义,支持继续使用获批的24mg/日起始剂量并按需调整剂量。

研究设计与样本

  • 双盲随机研究,患者随机接受仑伐替尼24mg/日或18mg/日。
  • 主要疗效终点为第24周客观缓解率(ORRwk24),非劣效性界值为优势比0.4。
  • 主要安全性终点为第24周≥3级治疗中出现的不良事件(TEAE)频率。

主要发现

  • ORRwk24在24mg组为57.3%(95%CI 46.1,68.5),18mg组为40.3%(95%CI 29.3,51.2)。
  • 优势比(18/24mg)为0.50(95%CI 0.26,0.96)。
  • 第24周≥3级TEAE发生率在24mg组为61.3%,18mg组为57.1%,差异-4.2%(95%CI -19.8,11.4)。

关键数值与推荐

  • 非劣效性界值:优势比0.4。
  • ORRwk24:24mg组57.3%(95%CI 46.1,68.5),18mg组40.3%(95%CI 29.3,51.2)。
  • 优势比(18/24mg):0.50(95%CI 0.26,0.96)。
  • ≥3级TEAE率:24mg组61.3%,18mg组57.1%,差异-4.2%(95%CI -19.8,11.4)。

临床怎么用

  • RR-DTC患者应继续使用仑伐替尼获批的24mg/日起始剂量。
  • 治疗过程中可根据需要调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored, in a double-blinded fashion, whether a starting dose of 18 mg/day would provide comparable efficacy with reduced toxicity. METHODS: Patients with RR-DTC were randomized to lenvatinib 24 mg/day or 18 mg/day. The primary efficacy endpoint was objective response rate as of week 24 (ORRwk24); the odds ratio noninferiority margin was 0.4. The primary safety endpoint was frequency of grade ≥3 treatment-emergent adverse events (TEAEs) as of week 24. Tumors were assessed using RECIST v1.1. TEAEs were monitored and recorded. RESULTS: The ORRwk24 was 57.3% (95% CI 46.1, 68.5) in the lenvatinib 24-mg arm and 40.3% (95% CI 29.3, 51.2) in the lenvatinib 18-mg arm, with an odds ratio (18/24 mg) of 0.50 (95% CI 0.26, 0.96). As of week 24, the rates of TEAEs grade ≥3 were 61.3% in the lenvatinib 24-mg arm and 57.1% in the lenvatinib 18-mg arm, a difference of -4.2% (95% CI -19.8, 11.4). CONCLUSION: A starting dose of lenvatinib 18 mg/day did not demonstrate noninferiority compared to a starting dose of 24 mg/day as assessed by ORRwk24 in patients with RR-DTC. The results represent a clinically meaningful difference in ORRwk24. The safety profile was comparable, with no clinically relevant difference between arms. These results support the continued use of the approved starting dose of lenvatinib 24 mg/day in patients with RR-DTC and adjusting the dose as necessary.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Brose MS, Panaseykin Y, Konda B, et al. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022. PMID: 34664662. doi:10.1210/clinem/dgab731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。